Medicinova Says Positive Phase 2 Results in 2 Asthma Studies
MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq: MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), today announced the publication of positive Phase 2 clinical results in two asthma studies in the Journal of Asthma. The publication is entitled, "Evaluation of Bedoradrine Sulfate (MN-221), a Novel, Highly Selective Beta(2)-Adrenergic Receptor Agonist for the Treatment of Asthma via Intravenous Infusion" and is available online.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.